![Peter Wirth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Wirth
Directeur/Membre du Conseil chez
ZAI LAB LIMITED
Fortune : 7 M $ au 31/05/2026
Profil
Peter Karl Wirth was the founder of Lysosomal Therapeutics, Inc., founded in 2011, where the title held was President & Director from 2011 to 2014.
Current jobs include Chairman at Forma Therapeutics, Inc., Director at Centrexion Therapeutics Corp., and Independent Director at Zai Lab Ltd. since 2020.
Former jobs include Chairman at Forma Therapeutics Holdings, Inc. from 2012 to 2022, Executive Chairman at ZappRx, Inc. from 2016 to 2018, Chairman at Syros Pharmaceuticals, Inc. from 2017 to 2025, Director at EPIX Pharmaceuticals, Inc., Director at Aura Biosciences, Inc. from 2013 to 2017, Independent Director at Synageva BioPharma Corp.
from 2013 to 2015, Secretary, Chief Risk Officer & Executive VP-Legal at Genzyme Corp.
from 2009 to 2011, Head-Technology Group & Partner at Palmer & Dodge LLP, and Venture Partner at Quan Capital Management (US) LLC from 2018 to 2023.
Education includes undergraduate degree from the University of Wisconsin in 1972 and graduate degree from Harvard Law School in 1975.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ZAI LAB LTD. 0,35 % | 10/04/2026 | 3 937 500 ( 0,35 % ) | 7 M $ | 31/05/2026 |
Postes actifs de Peter Wirth
| Sociétés | Poste | Début |
|---|---|---|
| ZAI LAB LIMITED | Directeur/Membre du Conseil | 01/01/2017 |
| CENTREXION THERAPEUTICS CORPORATION | Directeur/Membre du Conseil | - |
Forma Therapeutics, Inc.
 Forma Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines for cancer and other genetically driven diseases | Président | - |
Anciens postes connus de Peter Wirth
| Sociétés | Poste | Fin |
|---|---|---|
| SYROS PHARMACEUTICALS, INC. | Président | 28/02/2025 |
Quan Capital Management (US) LLC
 Quan Capital Management (US) LLC Finance/Rental/LeasingFinance The company is based in Palo Alto, CA. The company focuses on discovering, incubating, and growing healthcare companies with innovative solutions, and provides support through strategy, operations, and development, as well as building strategic alliances and networks worldwide. Founded in 2018, Quan Capital Management (US) LLC is a venture capital firm specializing in early and growth-stage investments in the life sciences sector, including therapeutic biotech, pharmaceuticals, enabling technologies, high-end specialty services, and precision medicine. | Corporate Officer/Principal | 31/08/2023 |
| FORMA THERAPEUTICS HOLDINGS, INC. | Président | 14/10/2022 |
ZappRx, Inc.
 ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services Offers communication related services to pharmaceutical & healthcare providers | Président | 01/05/2018 |
| AURA BIOSCIENCES, INC. | Directeur/Membre du Conseil | 01/12/2017 |
Formation de Peter Wirth
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops pharmaceuticals | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Forma Therapeutics, Inc.
Forma Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines for cancer and other genetically driven diseases | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes novel therapeutics to transform the patient living | Health Technology |
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops therapies for chronic pain and autoimmune disease | Health Technology |
Palmer & Dodge LLP
 Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
Syros Pharmaceuticals, Inc.
 Syros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which developing care for the frontline treatment of patients with hematologic malignancies | Health Technology |
ZappRx, Inc.
ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services Offers communication related services to pharmaceutical & healthcare providers | Commercial Services |
Harvard Law School
 Harvard Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecules for use in the treatment of neurodegenerative diseases | Health Technology |
Zai Lab Ltd.
 Zai Lab Ltd. BiotechnologyHealth Technology Develops medicine for cancer, autoimmune and infectious diseases | Health Technology |
Quan Capital Management (US) LLC
Quan Capital Management (US) LLC Finance/Rental/LeasingFinance The company is based in Palo Alto, CA. The company focuses on discovering, incubating, and growing healthcare companies with innovative solutions, and provides support through strategy, operations, and development, as well as building strategic alliances and networks worldwide. Founded in 2018, Quan Capital Management (US) LLC is a venture capital firm specializing in early and growth-stage investments in the life sciences sector, including therapeutic biotech, pharmaceuticals, enabling technologies, high-end specialty services, and precision medicine. | Finance |
